Idenix Pharma (DIX) Says IDX184 Demonstrated High Level of Resistance to In Vitro, Antiviral Acitivity

Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), has announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection. IDX184, a pan-genotypic oral nucleotide polymerase inhibitor, has demonstrated a high barrier to resistance in vitro and potent antiviral activity in both preclinical and clinical studies.

For more color, click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Albemarle names Max Hood as chief accounting officer
• LiveRamp shrinks board to six directors after resignation
• Virtus Investment Partners names Jack Boyce to its board